Professor Mark Morrison

Chair and Principal Group Leader


    About me

    Mark Morrison’s scientific expertise resides in the fields of microbial physiology, genetics, and genomics, with a career-long focus on the gastrointestinal microbiota of humans and other herbivores. He is committed to the translation of microbial genomic and metagenomic datasets into a sound biological framework, producing novel diagnostic, organismal, and enzyme-based technologies.  During his academic tenure in the USA, he led the team that produced the first genome sequences for gut Ruminococcus and Prevotella spp. Both genera are now widely acknowledged to play a key role in establishing human gut “enterotypes”. He returned to Australia in 2006 as a CSIRO Science Leader, leading the gut health stream of their Preventative Health Flagship Program, and one of CSIRO’s five Capability Platforms (in Transformational Biology). He joined the University of Queensland Diamantina Institute in October 2013 and created nationally unique infrastructure for microbe isolation in support of UQ’s germ-free and gnotobiotic small animal facility at the Translational Research Institute. He currently serves as science lead for gastrointestinal function with the Princess Alexandra Hospital’s Department of Gastroenterology and Hepatology and leads the microbiome research for the NHMRC Centre for Research Excellence in Digestive Health. He is also Australia’s science representative to the International Human Microbiome Consortium and serves on other international academic and industry advisory boards for gut microbiome research.



    Government Reports:

    1. Morrison M, Hugenholtz P. Microbiomics. In: Williamson R, et al. (Eds) “The future of precision medicine in Australia” pp. 43-45. 2018 Report for the Australian Council of Learned Academies.


    1. Keely S, Morrison M, Burns G, Talley N. “Diagnostic marker for functional gastrointestinal disorders” Australian Provisional Patent Application 2021901692, submitted 07/06/2021, via the University of Newcastle and UniQuest (University of Queensland).
    2. Ziemer C, Arcidiacono S, Ragauskas A, Morrison M. “Novel Fibro-biotic bacterium isolate” Patent US20110076356 A1 published 31/03/2011 via the United States Department of Agriculture.

    Three Recent  Publications:

    1. Teh, J-J, Berendsen EM, Hoedt EC, Kang S, Zhang J, Zhang F, Liu Q, Hamilton AL, Wilson-O'Brien A, Ching J, Sung JJY, Yu J, Ng SC, Kamm MA, Morrison M. Novel strain-level resolution of Crohn's disease mucosa-associated microbiota via an ex vivo combination of microbe culture and metagenomic sequencing. ISME Journal. 2021. online ahead of print. doi: 10.1038/s41396-021-00991-1.  
    2. Zhang J, Hoedt EC, Liu Q, Berendsen E, Teh JJ, Hamilton A, O' Brien AW, Ching JYL, Wei H, Yang K, Xu Z, Wong SH, Mak JWY, Sung JJY, Morrison M*, Yu J*, Kamm MA*, Ng SC*. Elucidation of Proteus mirabilis as a key bacterium in Crohn's Disease inflammation. Gastroenterology. 2021. 160:317-330.e11
    3. Shah A, Talley NJ, Koloski N, Macdonald GA, Kendall BJ, Shanahan ER, Walker MM, Keely S, Jones MP, *Morrison M, *Holtmann GJ. Duodenal bacterial load as determined by quantitative polymerase chain reaction: asymptomatic controls, functional gastrointestinal disorders and inflammatory bowel disease. Alim Pharmacol Ther. 2020. 52:155-167.

    List of Published Work in MyBibliography:

    Research fields

    Microbial Biology, Genetics and (Meta)genomics